Summary: Granulosa cell tumors (GCTs) comprise 2% to 5% of ovarian neoplasms, with unpredictable patterns of recurrence. The HER family, GATA4, and SMAD3 genes are reportedly involved in GCT proliferation and apoptosis and may serve as new predictors of recurrence. The aim of the study was to evaluate novel predictors of recurrence in GCT from a large single institution cohort. Patients diagnosed with GCTs (n = 125) between 1975 and 2014 were identified. Clinicopathologic parameters were obtained and immunohistochemical evaluation was performed of calretinin, inhibin, HER2, CD56, SMAD3, and GATA4. Statistical analyses were conducted using Fisher exact test and Kaplan-Meier survival curves and Cox regression analysis. The median follow-up period was 120 months (range, 1-465 mo). Recurrence was noted in 12/125 (9.6%) patients. Kaplan-Meier analysis showed a shorter mean disease-free interval in whites versus blacks (P = 0.001), stage III-IV versus stage I-II (P = 0.0001), patients treated with surgery+chemotherapy versus surgery (P = 0.0001), mitotic rate Z4 (P = 0.005), severe nuclear pleomorphism (P = 0.013), high HER2 expression (P = 0.001), high CD56 expression (P = 0.001), and high SMAD3 expression (P = 0.001). On Cox regression analysis, SMAD3 and type of treatment received were the only 2 independent prognostic factors for diseasefree interval (P = 0.03 and P = 0.007, respectively). On subanalysis for early-stage (stage I) GCTs, the need for adjuvant chemotherapy and high expression of SMAD3 continued to be independent predictors of recurrence (HR = 10.2, P = 0.01 and HR = 8.9, P = 0.001, respectively).
Ovarian granulosa cell tumors (GCTs) represent approximately 2% to 5% of all ovarian cancers. They are the most common type of ovarian sex-cord stromal tumors (1) . GCTs are divided histologically into juvenile and adult forms. Adult granulosa cell tumor (AGCTs) account for 95% of GCTs with a median age at diagnosis of 50 to 55 years (2) . GCTs have malignant potential but fortunately, the majority of patients present with stage I disease, for which the long-term disease-free survival is approximately 84% to 95% (3, 4) . Many of these patients are cured by surgery but insidious recurrence is still reported in up to 20% to 30%, even in early-stage disease (5, 6) . Because complete tumor resection is a significant prognostic factor (5, 7) and because of the indolent nature of GCTs, routine staging has been traditionally recommended with the exception when there is a need for fertility-sparing surgery.
Although prognostic indicators have long been studied, predicting the likelihood of recurrence with certainty remains elusive; hence, postoperative management is usually based on stage of disease, completeness of tumor resection/presence of residual tumor, and whether fertility-sparing surgery is performed.
Chemotherapy has been used for extensive residual disease and inoperable metastases/recurrences (8) (9) (10) . Choice of ideal candidates as well as standard postoperative adjuvant therapy is yet to be determined (11) , hence the need for more accurate clinical and pathologic predictors of the clinical behavior of GCT.
Prognostic factors investigated can be divided into clinical as well as pathologic factors. Clinical prognostic factors include age (1, 12, 13) , tumor size (1, 12, 14) , stage of disease (12) (13) (14) (15) (16) , extent of surgery (3, 15) , and residual disease/tumor rupture (5, 7) . Pathologic factors include tumor histology (4, 17) , mitotic index (MI) (7, 17, 18) , nuclear atypia (19) , and expression of inhibin, epidermal growth factor (EGFR), and Ki67 (20, 21) .
With the recent diagnosis of the missense point mutation c4024G (codon C134W) in the gene coding for Forkhead Box L2 (FOXL2) transcription factor in 90% to 97% of GCTs (22) , FOXL2 pathways were investigated with the aim of identifying new prognostic factors. Absence of and increased FOXL2 expression were described as poor prognostic factors (23, 24) . Aberrant granulosa cell proliferation and apoptosis have been recently implicated in the pathogenesis of GCTs secondary to interactions between C134-mutated FOXL2, SMAD3, and GA-TA4 (25) . SMAD3, a transcription factor in the tumor growth factor-b (TGF-b) signaling pathway, activates NF-kB which increases cell viability in human GCT cells through a positive feedback loop (26) . In murine cell models, SMAD3 interacts with the GATA4, suggesting the involvement of GATA4 in TGF-b signaling pathway as well (27) . GATA4 is a zinc finger transcription factor that plays an important role in granulosa cell function and development (27, 28) , and has recently been associated with advanced stage GCT and increased recurrence risk (29) because of its antiapoptotic effect (30) .
Increased expression of human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor, is prognostic of aggressive disease in breast, gastric, and epithelial ovarian cancer (31, 32) with inconsistency in its expression in GCTs; positive in some studies (33, 34) and negative in others (35, 36) .
CD56 is a membrane-bound cell surface sialoglycoprotein and a member of the immunoglobulin supergene family, which induces cell-to-cell interactions during embryonic development, cell migration, and organogenesis (37) .
CD56 is expressed by most neuroectodermalderived cell lines and different tumors and its expression is associated with poor prognosis in a subset of squamous cell carcinoma and renal cell carcinoma (38) . CD56 expression in primordial follicles and theca cells was described to have a role in folliculogenesis (39) . CD56 expression in GCTs was suggested to be secondary to acquisition of CD56 immunoreactivity during neoplastic transformation or because GCTs originate from theca cells rather than granulosa cells (40) . Expression of CD56 was described in primary and recurrent GCT but not as a predictor of recurrence (41) .
We report a review of patients diagnosed with GCTs from a single large institution with the aim of identifying new predictors of recurrence, which could aid in patient counseling and decision making postoperatively and providing more targeted therapy.
MATERIALS AND METHODS
After obtaining Institutional Review Board approval, patients diagnosed with GCTs (n = 125) between 1975 and 2014 were identified. Clinical parameters (age, race, body mass index, treatment, time to recurrence, and vital status) and pathologic variables (histologic type, tumor size, and stage) were obtained from electronic medical records and pathology records. Tumor stage was assigned according to the International Federation of Gynecology and Obstetrics (FIGO) criteria (42) . Morphologic features including mitotic rate, nuclear pleomorphism (NP), and histologic patterns were evaluated from review of whole-tissue sections of each tumor. Mitotic rate was assessed by enumerating the number of mitotic figures in 10 consecutive HPFs ( Â 400, field diameter = 0.55 mm); <4/10 HPF is low and Z4/10 HPF is high. Immunohistochemical (IHC) evaluation was performed on tissue microarrays for 88 primary GCT cases. Tissue microarrays were constructed from formalin-fixed, paraffin embedded blocks using a duplicate of 1-mm-diameter core obtained from a representative area of each tumor (43) . The antibodies used were SMAD3 (Catalog no. 51-1500, 1:100 dilution; Invitrogen, Camarillo, CA), VEGF (sc-152, 1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), Her2 (sc-33684, 1:50-1:500 dilution; Santa Cruz Biotechnology), Inhibin (mcA951ST, 1:25 dilution; Serotec, Raleigh, NC), Calretinin (PA5-16681, dilution 1:100; Life Technologies, Chicago, IL), CD56 (123C307-5603, 1:100 dilution; Invitrogen, Carlsbad, CA), and GATA4 (LS-B7989, 1:100 dilution; Lifespan Biosciences Inc.). Immunostaining was performed using heat-induced epitope retrieval. Slides were blocked with 3% H 2 O 2 and then incubated with the antibody for 1 hour at 371C. Detection of antibody binding was obtained using Optiview (Ventana) after a polymer-based amplification step (Ultraview; Ventana). Slides were then counterstained with hematoxylin and coverslipped. Positive controls were used; for calretinin, mesothelioma tissue section; for inhibin, adrenal gland tissue section; for CD56, brain tissue section; for GATA4, prostate tissue section; for HER2, HER2-positive breast tumor tissue section; and for SMAD3, breast tissue was used. With regards to negative controls, ovarian tissue section without any pathology was used. All diagnoses and IHC reads were confirmed by 2 gynecologic oncology pathologists and in a few cases, where discrepancy was noted, a multihead microscope was used to discuss the areas of discrepancy to reach a consensus on the final read.
H Score
Each marker was scored for % and intensity and H score was established by combining both. Expression of GATA4 was categorized as negative for 0%, low for <80% with +1 nuclear staining, intermediate for <80% with +2/+3 or for >80% with +1, and high for Z 80% with +2/+3 staining (25) . Expression of inhibin was categorized as negative for 0%, low for r50% with +1 cytoplasmic staining, intermediate for r50% with +2/+3 or >50% with +1, and high for >50% with +2/+3 staining (44); for SMAD3, negative for 0%, low for any % with +1 cytoplasmic staining, intermediate for <70% with +2/+3, and high for Z70% with +2/+3 staining (25); for VEGF, negative for <20% with +1 cytoplasmic staining, low for 20% to <60% with +2, intermediate for r60% with +1/+3 or >60% with +1/+2, and high for >60% with +3 staining (45) . Scoring of membranous antigen for Her2 was negative for 0%, low for <80% with +1 staining, intermediate for <80% with +2/ +3 or Z80% with +1, and high for Z80% with +2 or +3 staining (19) . Scoring for membranous and cytoplasmic antigen for CD56 was negative for 0%, low for <50% with +1 or +2 staining, intermediate for <50% with +3 or Z50% with +1/+2, and high for Z50% with +3 staining (46) . Expression of calretinin was scored as low for <50% with +1 nuclear and cytoplasmic staining, intermediate for r50% with +2/+3 or >50% with +1, and high for >50% with +2/+3 staining (44) . Figure 1 illustrates the different IHC stains used. Statistical analyses were conducted using Fisher exact test (2-tailed) and Kaplan-Meier (KM) survival curves. Significance was set at Po0.05.
RESULTS
The patient clinical characteristics (125 patients with the diagnosis of primary GCT) with respect to recurrence were analyzed using w 2 and Fisher exact test to perform univariate analyses and are summarized in Table 1 . The median follow-up period was 120 months (range, 1-465 mo). Recurrence was noted in 12/125 (9.6%) patients and was significantly higher in whites and patients who had surgery and chemotherapy (P = 0.001 and 0.0001, respectively). Earlystage GCT (stages I-II) were significantly less likely to have a recurrence as compared with stages III-IV (P = 0.001). Patients with recurrent GCT had a shorter overall survival (83 vs. 138 mo) and diseasefree interval (DFI) (60 vs.135 mo), without a statistical difference noted.
Histomorphologic Features and Tumor Characteristics Associated With Recurrent GCT
AGCT comprised the majority of patients (113/ 125, 90%) and 12 (10%) patients were juvenile type (JGCT) ( Table 2 ). Tumors with a mitotic rate Z4/10 HPF and severe NP were found to have a significantly higher likelihood of recurrence (P = 0.021 and 0.016, respectively). JGCT were more likely to recur (2/12, 17%) as compared with AGCT (10/113, 9%). Tumor subtype, size, and capsule rupture did not show a significant effect on recurrence.
Univariate analysis for IHC assessment of protein expression is illustrated in Table 3 . High levels of Inhibin, HER2, CD56, and SMAD3 expression were significantly associated with increased recurrence (P = 0.02, 0.014, 0.001, and 0.0001, respectively). On multivariate logistic regression analysis of clinicopathologic variables, treatment type continued to have a significant impact on recurrence, with the addition of chemotherapy to surgery predicting increased likelihood of recurrence by 59-fold (P = 0.001; 95% CI, 5.39-646.34). Mitotic count Z4/10 HPF and high levels of expression of CD56 and SMAD3 were also found to be independent predictors of recurrence (OR = 13.3, P = 0.038; OR = 9.8, P = 0.04; and OR = 14.2, P = 0.001, respectively) ( others, respectively, P = 0.001), stage III-IV versus stage I-II (77.2 vs. 432.4 mo, P = 0.0001), and in patients treated with surgery+chemotherapy versus surgery (73.5 vs. 227.2 mo) (P = 0.0001). It is noted that the chemotherapy-only group had longer DFI, but these were 2 patients only and the results were censored.
Also, shorter mean DFI was noted in patients with mitotic rate Z4 (162.3 vs. 432.9 mo, P = 0.005), severe NP (104.2 vs. 181.2 vs. 440.5 mo, P = 0.013), high HER2 expression (89.0 vs. 401.6 mo, P = 0.001), high CD56 expression (156.8 vs. 453.9 mo, P = 0.001), and high SMAD3 expression (220.6 vs. 441.5 mo, P = 0.001) (Fig. 2) . On Cox regression analysis, SMAD3 and the need for adjuvant chemotherapy were the only 2 independent prognostic factors for DFI (P = 0.03 and P = 0.007, respectively) (Table 4) .
To evaluate the utility of the prognostic factors in early-stage (stage 1) GCTs, a subanalysis was performed (Table 5 and 6 and Fig. 3 ). Treatment (need for adjuvant chemotherapy), and high expression of CD56 and SMAD3 were found to be significant predictors of recurrence on univariate analysis (Table 5 ), but only treatment was found to be an independent predictor of recurrence on multivariate analysis (P = 0.01) ( Table 7) .
In KM analysis, a significantly shorter DFI was noted with the surgery+chemotherapy treatment group and with high expression of CD56 and SMAD3 (P = 0.0001, P = 0.008, and P = 0.0001, respectively) (Fig. 2) . We further investigated the value of high simultaneous expression of CD56 and SMAD3 in stage I GCT. Although significant on univariate and KM analysis (P = 0.007 and P = 0.04), simultaneous high expression of CD56 and SMAD3 showed a tendency toward significance on multivariate analysis (P = 0.05). Given that treatment is not an inherent characteristic in patients, repeat Cox regression analysis in stage I (excluding treatment) showed that high expression of SMAD3 was significantly associated with increased risk of recurrence (HR = 8.9; 95% CI, 2.34-34.5; P = 0.001). Tables 7 and 8 summarize the clinicopathologic characteristics of the 12 patients who developed a recurrence.
DISCUSSION
GCTs are low-grade malignant neoplasms, in which intraoperative and postoperative management decisions are challenging often times. This stems from the rarity of GCTs and the need for prolonged follow-up periods, which limit the availability of high-quality evidence. Recurrences after therapy have typically occurred within 5 to 10 years (47, 48) , and up to as long as 37 years (49), which makes the establishment of reliable prognostic indicators or predictors of recurrence a challenge. This may account for the discrepancy noted in the overall 10-year versus the 25-year survival in AGCTs in general and in stage I; 60% to 90% versus 40% to 60% and 85% to 95% versus 69% to 90%, respectively (47, 48, 50, 51) . As the majority (60%-90%) of GCTs present with stage I disease (52), the development of reliable predictors of recurrence may help in identifying early-stage GCTs with a higher likelihood for recurrence that may have gone without adjuvant therapy or inadequately followed after surgery. We sought to investigate some of the previously studied clinicopathologic prognostic factors and to explore novel markers of recurrence.
Of the clinical factors investigated, patient's age and tumor size/rupture remain to be of controversial prognostic value. Although some studies support worse prognosis with older age (1, 12) , tumor size >10 to >15 cm (53, 54) , and tumor rupture (16) , others as in our study do not (16, 18, 51, 55) .
In contrast, stage of disease has been consistently shown to be the most important independent prognostic factor with long-term follow-up studies showing the 10-year survival to be 84% to 95%, 50% to 65%, and 17% to 33% for stage I, II, and III-IV, respectively (3, 13) .
Although in our study, a significant difference was only noted on univariate and KM analyses for stage but not on multivariate analysis, this may have been explained by the relatively small sample size and the majority of patients being in early stage. In addition, the significant association of chemotherapy administration (reflective of disease stage) and recurrence may support the anticipated effect of stage on prognosis/recurrence.
However, in a subanalysis of stage I, patients receiving adjuvant chemotherapy (stage IC, residual disease) were significantly more likely to have a recurrence and to have a shorter DFI (OR = 17.25; 95% CI, 1.73-172.02; P = 0.01 and 104.3 vs. 58.9 mo, P = 0.0001).
In some studies, postoperative chemotherapy showed a clinical benefit in advanced stage and recurrent disease (56) (57) (58) (59) , but others failed to show any improvement in progression-free survival (PFS) and overall survival with the addition of chemotherapy (6, 53, (60) (61) (62) . In agreement with our study, Meisel et al (63) reported that patients who did not receive adjuvant chemotherapy had a significantly longer median PFS and a significantly higher 3-year PFS rate than those that did.
The efficacy of pathologic factors (MI, NP) as predictors of recurrence remains controversial partly because of the subjectivity (interobserver variation), use of different cutoffs, and not controlling for stage. Some studies reported a worse prognosis with increased NP (12, 47) and MI (different cutoffs >3 to >10) (12, 14, 16, 17, 64) , whereas others reported no prognostic significance (1, 34, 51, 55, 65) . In agreement with the findings of Fox and colleagues and Lassus and colleagues, the subanalysis performed in our study showed no predictive value for MI in earlystage (stage I) GCTs. However, the mitotic rate was found to be an independent predictor of recurrence on logistic regression analysis of the whole data with a greater likelihood for recurrence with a mitotic rate Z4. This may be explained by possible skewness of the data by the higher stage GCTs, and thus highlights the importance of performing subanalysis on early-stage GCTs.
Although high serum levels of and high expression of VEGF were noted in GCT (45), 1 study failed to show a prognostic significance in predicting recurrence/PFS as shown in our study (66) . Also, even though GATA4 was recently found to be an independent predictor of recurrence (19) , our data failed to show any prognostic utility for GATA4 as well as HER2 (33, 35) . However, expression of HER2 may be of importance in predicting resistance to treatment with bevacizumab.
CD56 has been recently found to be expressed in primary and recurrent GCTs (39) , with a high degree of sensitivity for sex-cord stromal tumors (46) . In our study, high expression of CD56 independently predicted a higher likelihood of recurrence and a significantly longer DFI.
The expression of SMAD3 in GCTs has not been studied before. High expression of SMAD3 independently predicted a higher likelihood of recurrence and a significantly longer DFI. In addition, on a subanalysis for early-stage (stage I) GCTs, high expression of CD56 or SMAD3 showed a significant prediction of recurrence on univariate analysis only; however, simultaneous high expression of CD56 and SMAD3 predicted a higher likelihood of recurrence and significantly shorter DFI on multivariate analysis. More importantly, the true utility of SMAD3 in predicting recurrence in early-stage GCTs was illustrated upon exclusion of treatment (which is not an inherent characteristic of patients) from the analysis. High expression of SMAD3 was the only independent predictor of recurrence. This may prove to be a useful tool in counseling patients postoperatively about recurrence risk, closer surveillance, and need for chemotherapy and may prove to be a future therapeutic target.
Ideally, a predictive model for recurrence of earlystage (stage I) GCTs could be developed based on combining clinical and pathologic factors. An example of such model was suggested by Nosov et al. (20) , where it was suggested that patients younger than 48 years whose tumor has a higher expression of inhibin and Ki67 are at a higher risk for recurrence and hence would benefit from adjuvant chemotherapy. Another model predicting recurrence-free survival in a retrospective cohort of 127 patients from multiple institutions created a nomogram based on clinical stage, body mass index, tumor diameter, and MI (67) .
Appreciable differences are noted among different studies as well as our study with regards to the degree of expression of different pathologic prognostic factors, which are potential therapeutic targets (such as VEGF, HER2). Also potential novel pathologic prognostic factors/therapeutic targets (SMAD3 and other TGF-b pathway targets) are being investigated. In an era of precision medicine, individualizing patient care postoperatively and making a choice of adjuvant chemotherapy based on which of these IHC pathologic factors is highly expressed, patients (determined to be at higher risk for recurrence) can be treated with bevacizumab (45, 68) , trastuzumab/ imatinib (69), peptide aptemers, and ligand traps/ antisense oligonucleotides (70) if they have GCTs that have a high expression of VEGF, HER2, SMAD3, and TGF-b receptor, respectively.
Our study is not without limitations; this is a retrospective review with inherent bias but because of the rare nature of GCTs and tendency for late recurrence, this makes accruing patients in a prospective randomized study very difficult, even from multiple institutions. Also, the percentage of recurrence was relatively low (12/125, 9.6%), compared with higher reported rates of recurrence by other authors.
However, this review is one of the larger series published on GCTs from a single institution and spans over 39 years. Because many studies investigating prognostic factors in AGCTs do not include a pathologic review of the cases, one of the major strengths of our study is the stringent pathology review by the same gynecologic oncology pathologist to confirm the diagnosis. Also performing a subanalysis to predict recurrence and DFI in early-stage patients was rarely done in studies evaluating GCTs because of small sample size.
To the best of our knowledge, this is the first report of the utility of CD56 and SMAD3 IHC expression in primary GCTs as independent predictors of recurrence. This will need to be validated on a larger scale, possibly through multisite collaboration, to confirm the utility of these prognostic factors.
